Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Effectiveness and Toxicities of Modified DHAP Protocol With Standard DHAP Protocol in Patients With Relapsed/Refractory Diffused Large B-cell Lymphoma.

NCT07739654 is registered in ClinicalTrials.gov with King Edward Medical University as lead sponsor.

NCT NCT07739654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07739654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Effectiveness and Toxicities of Modified DHAP Protocol With Standard DHAP Protocol in Patients With Relapsed/Refractory Diffused Large B-cell Lymphoma.
Lead sponsor
King Edward Medical University
Phase
Phase 3
Overall status
Recruiting
Start date
March 18, 2026
Completion date
October 20, 2027
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl - diffuse large b cell lymphoma